Journal
CARBOHYDRATE POLYMERS
Volume 261, Issue -, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.carbpol.2021.117919
Keywords
Chitosan; Bacterial vaginosis; Vulvovaginal candidiasis; Trichomoniasis; Vaginitis
Categories
Funding
- Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -Brasil (CAPES) [001]
- Fundacao de Amparoa Pesquisa do Estado de Sao Paulo -Brasil (FAPESP) [2019/10261-2, 2019/25125-7]
Ask authors/readers for more resources
The review discusses the use of chitosan in developing mucoadhesive systems for the treatment of local vaginal infections. Studies have shown that chitosan as a component of DDS is a promising device for treating vaginal infectious diseases.
Vaginal administration is a promising route for the local treatment of infectious vaginal diseases since it can bypass the first-pass metabolism, drug interactions, and adverse effects. However, the commercial products currently available for topical vulvovaginal treatment have low acceptability and do not adequately explore this route. Mucoadhesive systems can optimize the efficacy of drugs administered by this route to increase the retention time of the drug in the vaginal environment. Several polymers are used to develop mucoadhesive systems, among them chitosan, a natural polymer that is highly biocompatible and technologically versatile. Thus, the present review aimed to analyze the studies that used chitosan to develop mucoadhesive systems for the treatment of local vaginal infections. These studies demonstrated that chitosan as a component of mucoadhesive drug delivery systems (DDS) is a promising device for the treatment of vaginal infectious diseases, due to the intrinsic antimicrobial activity of this biopolymer and because it does not interfere with the effectiveness of the drugs used for the treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available